Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
Saskatchewan Research Council is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Virent Energy Systems is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Senior Care Professionals is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer`s.